JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Gesloten

SectorGezondheidszorg

185.78 1.25

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

185.31

Max

185.87

Belangrijke statistieken

By Trading Economics

Inkomsten

27M

330M

Verkoop

104M

5.3B

K/W

Sectorgemiddelde

33.913

38.156

EPS

3.35

Dividendrendement

2.23

Winstmarge

6.259

Werknemers

70,000

EBITDA

93M

546M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+8.32% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.23%

2.50%

Volgende Winsten

7 aug 2025

Volgende dividenddatum

30 sep 2025

Volgende Ex Dividend datum

8 sep 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-15B

50B

Vorige openingsprijs

184.53

Vorige sluitingsprijs

185.78

Nieuwssentiment

By Acuity

16%

84%

20 / 375 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Becton Dickinson and Co Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jul 2025, 14:26 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 jul 2025, 11:08 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 jul 2025, 10:37 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

1 mei 2025, 11:18 UTC

Winsten

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

15 jul 2025, 18:32 UTC

Acquisities, Fusies, Overnames

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Acquisities, Fusies, Overnames

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 jul 2025, 16:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 jul 2025, 15:06 UTC

Acquisities, Fusies, Overnames

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 jul 2025, 14:11 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 jul 2025, 10:53 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 jul 2025, 10:22 UTC

Acquisities, Fusies, Overnames

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 jul 2025, 10:21 UTC

Acquisities, Fusies, Overnames

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 jul 2025, 10:20 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 jul 2025, 10:19 UTC

Acquisities, Fusies, Overnames

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 jul 2025, 10:19 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 jul 2025, 10:18 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 jul 2025, 10:18 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 jul 2025, 10:17 UTC

Acquisities, Fusies, Overnames

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 jul 2025, 10:16 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 jul 2025, 10:16 UTC

Acquisities, Fusies, Overnames

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14 jul 2025, 10:15 UTC

Acquisities, Fusies, Overnames

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14 jul 2025, 10:15 UTC

Acquisities, Fusies, Overnames

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

1 mei 2025, 10:33 UTC

Winsten

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1 mei 2025, 10:33 UTC

Winsten

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1 mei 2025, 10:32 UTC

Winsten

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1 mei 2025, 10:32 UTC

Winsten

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1 mei 2025, 10:31 UTC

Winsten

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1 mei 2025, 10:31 UTC

Winsten

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Peer Vergelijking

Prijswijziging

Becton Dickinson and Co Prognose

Koersdoel

By TipRanks

8.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 200.73 USD  8.32%

Hoogste 255 USD

Laagste 172 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Becton Dickinson and Co - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

13 ratings

4

Buy

9

Hold

0

Sell

Technische score

By Trading Central

167 / 206.99Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

20 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.